# Sacubitril + Valsartan

## Entresto 100mg

| 藥物代碼           | OENTR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Heart failure, chronic, Class II to IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 副作用             | common■Cardiovascular: Hypotension (18% )■Endocrine metabolic: Hyperkalemia (12% )■Neurologic: Dizziness (6% )serious■Renal: Renal failure (5% )■Other: Angioedema (0.5% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 禁忌               | ■Angioedema to prior ACE inhibitor or angiotensin II receptor blocker therapy ■Concomitant aliskiren use in diabetic patients ■Concomitant use of ACE inhibitors; do not administer within 36 hours of each other ■Hypersensitivity to sacubitril, valsartan, or any component of the product                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 藥物保存方式       | 室溫                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 用法用量           | Adult Concomitant use of an ACEI is contraindicated; allow a 36 hour washout period when switching from or to an ACEI.The recommended Initial dose is 100 mg twice daily.Double the dose after 2 to 4 weeks to the target maintenance dose:200 mg twice daily. ■ Not taking or previously taking low doses of an ACEI or ARB:Initial dose: 50 mg twice daily ■Renal Impairment: eGFR >=30 mL/minute/1.73 m2: No dosage adjustment necessary. eGFR <30 mL/minute/1.73 m2: Initial dose: 50 mg twice daily ■Hepatic Impairment: Mild impairment (Child-Pugh class A): No dosage adjustment necessary. Moderate impairment (Child-Pugh class B): Initial dose: 50 mg twice daily Severe impairment (Child-Pugh class C): Use not recommended (has not been studied). |
| 肝功能異常         | 需 調 整 劑 量  中度肝功能(Child-Pugh B)不全患者之建議起始劑量為每日2次50mg 依患者耐受情況,每2至4周加倍Entresto的劑量,達到每日2次200mg的目標維持劑量 重度肝功能不全患者不建議使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 附帶說明           | [仿單] ENTRESTOR 用於懷孕女性會對胎兒造成傷害。在妊娠第二、三期使用作用於腎素 - 血管收縮素系統的藥物，會降低胎兒腎功能並增加胎兒及新生兒疾病和死亡率。 如果懷孕，請改用其他藥物，並停用 ENTRESTOR。 然而，如果除了作用於腎素 - 血管收縮素系統的藥物，沒有其他適當替代藥物，或當本藥可救治母親性命時，請告知懷孕女性本藥物對胎兒的潛在風險。 Sacubitril: No data Valsartan: Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                                                                                                                                      |
| 哺乳期用藥建議     | Unknown 尚未建立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 附帶說明           | [仿單] 尚無資料顯示 sacubitril/valsartan 是否會排入人類的乳汁、對接受哺乳嬰兒的影響，或對母乳分泌的作用。 但sacubitril/valsartan 會排入大鼠的乳汁中。 由於接受哺乳嬰兒暴露於 sacubitril/valsartan 可能發生嚴重不良反應，不建議在哺乳期間接受 ENTRESTOR 治療。 Sacubitril: No data Valsartan: No Human Data—Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 注射劑給藥建議途徑 | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

